Takeda Pharmaceutical Company Limited announced new assignment of Directors. New assignment of Non-Audit and Supervisory Committee Directors effective June 24, 2020: Christophe Weber, Representative Director, President & Chief Executive Officer; Masato Iwasaki, President, Japan Pharma Business Unit; Andrew Plump, Director, President, Research & Development; Constantine Saroukos, Director, Chief Financial Officer; Masahiro Sakane, Director, Chair of the Board Meeting; Olivier Bohuon, External Director; Jean-Luc Butel, External Director; Ian Clark, External Director; Yoshiaki Fujimori, External Director; Steven Gillis, External Director; Shiro Kuniya, External Director; and Toshiyuki Shiga, External Director. New assignment of Audit and Supervisory Committee Directors effective June 24, 2020: Yasuhiko Yamanaka, Director, Full-time Audit & Supervisory Committee member; Koji Hatsukawa, External Director, Chairperson of Audit & Supervisory Committee; Emiko Higashi, External Director, Audit & Supervisory Committee member; and Michel Orsinger, External Director, Audit & Supervisory Committee member. New assignment of Compensation committee and Nomination committee: Compensation committee - Emiko Higashi (Chair), Olivier Bohuon, Ian Clark, Yoshiaki Fujimori. Nomination committee - Masahiro Sakane (Chair), Jean-Luc Butel, Steven Gillis, Toshiyuki Shiga, Michel Orsinger, Christophe Weber (Observer).